Podcast: Play in new window | Download
Without intervention, in 2050, everyone in the US population will either have Alzheimer’s disease or be caring for someone with Alzheimer’s disease.
That’s the state of where we’re at with cognitive decline. Right now, if you reach the age of 85, your chances of developing cognitive decline are 1 in 2. That’s right, 50%. But, BUT, new research is helping us understand the hidden drivers of cognitive decline and creating hope at the same time. Because now that we understand the origin of risk for an individual, we can prescribe specific interventions to circumvent that risk and prevent the disease altogether.
This is the amazing work of James Maskell and Dr. Kristine Burke, my guests on the show today. Dr. Burke is Co-PI of the EVANTHEA Study, a clinical trial designed to look at the impact of a precision medicine approach to Alzheimer’s disease. The initial results are astounding – with intervention, 91% of participants saw improvement in cognitive function. That’s better than any drug, lifestyle medicine, or treatment protocol we have to date by a long shot. These two join me today to talk about what those hidden drivers are, how precision medicine can help, who’s going to pay for it, and why this is so critically important to society at large.
Dr. Kristine Burke is a triple board-certified precision medicine physician and the Founder and Executive Medical Director of True Health Center for Precision Medicine in Northern California. She is also the Co-Founder and Chief Medical Officer of TruNeura who is advancing a scalable model for brain health that integrates clinical insight, data, and AI-supported decision tools.
James Maskell has spent the past decade innovating at the cross section of functional medicine and community. To that end, he created the Functional Forum, the world’s largest integrative medicine conference with record-setting participation online and growing physician communities around the world.